WHO Adds Semaglutide to Essential Medicines List 2026

The World Health Organization has added semaglutide, the active ingredient in Ozempic and Wegovy, to its Essential Medicines List for 2026, marking a significant regulatory milestone as Canada prepares for the arrival of generic versions.

Essential Medicines Designation Impact

The WHO's Essential Medicines List identifies medications considered most effective and safe to meet the priority health needs of populations. This designation typically influences national drug policies, procurement decisions, and insurance coverage frameworks worldwide.

The timing of this announcement coincides with the January 4, 2026 patent expiration for semaglutide in Canada, which has opened the door for generic manufacturers to enter the market. Health Canada is currently reviewing nine applications for generic semaglutide products.

Canadian Generic Timeline

Industry experts anticipate the first generic semaglutide approvals could arrive by spring 2026, with additional products expected throughout the year. Current generic applicants include:

• Sandoz Canada
• Apotex Inc.
• Teva Canada
• Taro Pharmaceuticals
• Aspen Pharmacare
• Vimy Pharma

These manufacturers are positioning to compete with Novo Nordisk's branded products, which currently retail at approximately $300-400 CAD monthly at major Canadian pharmacies including Shoppers Drug Mart, Costco, and Walmart.

Market Preparation

The WHO designation comes as Canadian benefit plan administrators prepare for the transition to lower-cost generic alternatives. Recent industry reports indicate that GLP-1 medications have become a major cost driver for employer drug plans, with expanded usage anticipated even as generic competition emerges.

Health Canada has also expanded access by approving new formulations, including the recent approval of Rybelsus, the first oral GLP-1 medication available in Canada. The agency issued a Notice of Compliance for additional Wegovy indications under its NOC/c policy in January 2026.

Global Access Implications

Canada represents the first major market where semaglutide patents have expired, making it a testing ground for generic competition. The WHO's essential medicines designation could accelerate similar patent challenges and generic development in other jurisdictions.

The organization conditionally recommended GLP-1 therapies in December 2025, setting the stage for the essential medicines listing. This progression reflects growing recognition of these medications' clinical importance in healthcare systems worldwide.

Monitoring Generic Availability

Canadians seeking to track generic semaglutide approvals and pricing can use tools like the generic semaglutide tracker and insurance coverage checker. Additional information about GLP-1 medications is available in the comprehensive FAQ section.

While generic versions are expected to significantly reduce costs, exact pricing and availability timelines remain dependent on Health Canada's review process and individual manufacturer launch strategies.

This article is for informational purposes only and does not constitute medical advice.